Fig. 1
Study flow chart. HER2, human epidermal growth factor receptor 2; MBC, metastatic breast cancer; T-DXd, trastuzumab deruxtecan.
Fig. 1 | Scientific Reports
Study flow chart. HER2, human epidermal growth factor receptor 2; MBC, metastatic breast cancer; T-DXd, trastuzumab deruxtecan.
